Study of Local Levobupivacaine Injection to Reduce Pain After Endoscopic Submucosal Dissection for Esophageal Lesions

What this Trial Is About

Researchers are evaluating the effect of local levobupivacaine on reducing post-procedural pain following endoscopic submucosal dissection ESD for esophageal lesions. This randomized controlled trial aims to compare the pain relief outcomes of levobupivacaine injection with no local pain treatment after esophageal ESD. Levobupivacaine, known for its analgesic effects and better safety profile compared to bupivacaine, has not yet been studied in this specific setting. Participants will be randomly assigned to one of two groups one receiving no local levobupivacaine during ESD, and the other receiving a submucosal injection of levobupivacaine during the esophageal ESD procedure. The study is double-blinded, meaning neither participants nor researchers know which treatment is given. The trial focuses on assessing pain relief shortly after the procedure and up to 14 days later. During the study, participants will undergo the standard esophageal ESD procedure with or without levobupivacaine injection. Pain levels will be monitored and recorded to evaluate the effectiveness of the intervention. The primary outcome is pain relief measured 90 minutes after the procedure, with additional assessments up to 14 days post-procedure. Participants will be closely observed for safety and treatment effects throughout the study duration.

Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions